Gastrointestinal Cancer

Patients With Treatment-Naïve RCC Achieve Superior QoL With Nivolumab/Cabozantinib

January 29, 2022

Patient-reported outcomes demonstrated that nivolumab plus cabozantinib was associated with improved quality of life, while sunitinib was associated with health-related deterioration, in treatment-naïve renal cell carcinoma.

Trastuzumab Deruxtecan Significantly Improves OS in Select Gastric/GEJ Cancer

January 22, 2022

Patients with HER2-positive gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma experienced a 40% reduced risk of mortality with fam-trastuzumab deruxtecan-nxki, compared with patients who received standard therapy.

Frontline Pembrolizumab Plus Chemo Does Not Show Superior OS Over Chemo Alone in PD-L1+ Gastric/GEJ Adenocarcinoma

January 21, 2022

Pembrolizumab plus chemotherapy did not induce clinically meaningful survival benefit, compared with chemotherapy alone, in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher.